Annual CFF
$28.22 M
+$47.17 M+248.91%
December 31, 2023
Summary
- As of March 6, 2025, OPRX annual cash flow from financing activities is $28.22 million, with the most recent change of +$47.17 million (+248.91%) on December 31, 2023.
- During the last 3 years, OPRX annual CFF has risen by +$30.12 million (+1584.63%).
- OPRX annual CFF is now -61.83% below its all-time high of $73.92 million, reached on December 31, 2021.
Performance
OPRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$532.00 K
+$383.00 K+41.86%
September 30, 2024
Summary
- As of March 6, 2025, OPRX quarterly cash flow from financing activities is -$532.00 thousand, with the most recent change of +$383.00 thousand (+41.86%) on September 30, 2024.
- Over the past year, OPRX quarterly CFF has dropped by -$184.00 thousand (-52.87%).
- OPRX quarterly CFF is now -100.76% below its all-time high of $70.18 million, reached on March 31, 2021.
Performance
OPRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$34.10 M
-$184.00 K-0.54%
September 30, 2024
Summary
- As of March 6, 2025, OPRX TTM cash flow from financing activities is $34.10 million, with the most recent change of -$184.00 thousand (-0.54%) on September 30, 2024.
- Over the past year, OPRX TTM CFF has increased by +$49.51 million (+321.32%).
- OPRX TTM CFF is now -53.93% below its all-time high of $74.02 million, reached on September 30, 2021.
Performance
OPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
OPRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +248.9% | -52.9% | +321.3% |
| 3 y3 years | +1584.6% | -150.3% | -53.9% |
| 5 y5 years | +224.9% | -569.5% | +53.7% |
OPRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -61.8% | +248.9% | -101.5% | +95.6% | -53.9% | +225.9% |
| 5 y | 5-year | -61.8% | +248.9% | -100.8% | +95.6% | -53.9% | +225.9% |
| alltime | all time | -61.8% | +248.9% | -100.8% | +95.6% | -53.9% | +225.9% |
OptimizeRx Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$532.00 K(-41.9%) | $34.10 M(-0.5%) |
| Jun 2024 | - | -$915.00 K(+43.0%) | $34.29 M(+23.7%) |
| Mar 2024 | - | -$640.00 K(-101.8%) | $27.71 M(-1.8%) |
| Dec 2023 | $28.22 M(-248.9%) | $36.19 M(<-9900.0%) | $28.22 M(-283.1%) |
| Sep 2023 | - | -$348.00 K(-95.4%) | -$15.41 M(-43.1%) |
| Jun 2023 | - | -$7.49 M(+5617.6%) | -$27.08 M(+40.0%) |
| Mar 2023 | - | -$131.00 K(-98.2%) | -$19.34 M(+2.1%) |
| Dec 2022 | -$18.95 M(-125.6%) | -$7.44 M(-38.1%) | -$18.95 M(+81.3%) |
| Sep 2022 | - | -$12.02 M(-4883.5%) | -$10.45 M(-492.5%) |
| Jun 2022 | - | $251.30 K(-2.6%) | $2.66 M(-33.5%) |
| Mar 2022 | - | $258.10 K(-75.6%) | $4.00 M(-94.6%) |
| Dec 2021 | $73.92 M(-3989.2%) | $1.06 M(-3.3%) | $73.92 M(-0.1%) |
| Sep 2021 | - | $1.09 M(-31.2%) | $74.02 M(+4.3%) |
| Jun 2021 | - | $1.59 M(-97.7%) | $70.97 M(+4.1%) |
| Mar 2021 | - | $70.18 M(+5969.4%) | $68.17 M(-3686.3%) |
| Dec 2020 | -$1.90 M(-108.6%) | $1.16 M(-159.1%) | -$1.90 M(-35.4%) |
| Sep 2020 | - | -$1.95 M(+61.0%) | -$2.94 M(+276.2%) |
| Jun 2020 | - | -$1.21 M(-1182.4%) | -$782.60 K(-103.6%) |
| Mar 2020 | - | $112.20 K(-1.0%) | $21.95 M(-1.0%) |
| Dec 2019 | $22.18 M(+155.4%) | $113.30 K(-45.1%) | $22.18 M(+0.2%) |
| Sep 2019 | - | $206.30 K(-99.0%) | $22.13 M(-1.1%) |
| Jun 2019 | - | $21.52 M(+6158.9%) | $22.38 M(+147.8%) |
| Mar 2019 | - | $343.80 K(+426.5%) | $9.03 M(+4.0%) |
| Dec 2018 | $8.69 M(-2327.1%) | $65.30 K(-85.5%) | $8.69 M(+0.8%) |
| Sep 2018 | - | $451.00 K(-94.5%) | $8.62 M(+5.5%) |
| Jun 2018 | - | $8.17 M(>+9900.0%) | $8.17 M(-2194.7%) |
| Mar 2018 | - | $0.00(0.0%) | -$390.00 K(0.0%) |
| Dec 2017 | -$390.00 K(+9.1%) | $0.00(0.0%) | -$390.00 K(0.0%) |
| Sep 2017 | - | $0.00(-100.0%) | -$390.00 K(0.0%) |
| Jun 2017 | - | -$390.00 K(<-9900.0%) | -$390.00 K(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$357.40 K(-108.2%) | $0.00(0.0%) | -$357.40 K(0.0%) |
| Sep 2016 | - | $0.00(0.0%) | -$357.40 K(-109.0%) |
| Jun 2016 | - | $0.00(-100.0%) | $3.99 M(0.0%) |
| Mar 2016 | - | -$357.40 K(<-9900.0%) | $3.99 M(-8.2%) |
| Dec 2015 | $4.35 M(+55.5%) | $0.00(-100.0%) | $4.35 M(0.0%) |
| Sep 2015 | - | $4.35 M(>+9900.0%) | $4.35 M(>+9900.0%) |
| Jun 2015 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2015 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2014 | $2.79 M(>+9900.0%) | $0.00(0.0%) | $2.79 M(0.0%) |
| Sep 2014 | - | $0.00(0.0%) | $2.79 M(0.0%) |
| Jun 2014 | - | $0.00(-100.0%) | $2.79 M(0.0%) |
| Mar 2014 | - | $2.79 M(>+9900.0%) | $2.79 M(>+9900.0%) |
| Dec 2013 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2011 | $442.50 K(-79.5%) | -$57.50 K(-111.5%) | $442.50 K(-61.5%) |
| Sep 2011 | - | $500.00 K(>+9900.0%) | $1.15 M(+76.9%) |
| Jun 2011 | - | $0.00(0.0%) | $650.00 K(-69.9%) |
| Mar 2011 | - | $0.00(-100.0%) | $2.16 M(0.0%) |
| Dec 2010 | $2.16 M(+6863.5%) | $650.00 K(>+9900.0%) | $2.16 M(+39.8%) |
| Sep 2010 | - | $0.00(-100.0%) | $1.54 M(0.0%) |
| Jun 2010 | - | $1.51 M(+4210.9%) | $1.54 M(+4880.0%) |
| Dec 2009 | $31.00 K(-99.1%) | $35.00 K(>+9900.0%) | $31.00 K(-1248.1%) |
| Sep 2009 | - | $0.00(-100.0%) | -$2700.00(-100.1%) |
| Jun 2009 | - | -$4000.00(-407.7%) | $2.87 M(-12.9%) |
| Dec 2008 | $3.30 M(+499.5%) | $1300.00(-100.0%) | $3.30 M(+0.0%) |
| Sep 2008 | - | $2.87 M(+6858.1%) | $3.30 M(+680.5%) |
| Jun 2008 | - | $41.30 K(-89.2%) | $422.30 K(+10.8%) |
| Mar 2008 | - | $381.00 K | $381.00 K |
| Dec 2007 | $550.00 K | - | - |
FAQ
- What is OptimizeRx annual cash flow from financing activities?
- What is the all time high annual CFF for OptimizeRx?
- What is OptimizeRx annual CFF year-on-year change?
- What is OptimizeRx quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for OptimizeRx?
- What is OptimizeRx quarterly CFF year-on-year change?
- What is OptimizeRx TTM cash flow from financing activities?
- What is the all time high TTM CFF for OptimizeRx?
- What is OptimizeRx TTM CFF year-on-year change?
What is OptimizeRx annual cash flow from financing activities?
The current annual CFF of OPRX is $28.22 M
What is the all time high annual CFF for OptimizeRx?
OptimizeRx all-time high annual cash flow from financing activities is $73.92 M
What is OptimizeRx annual CFF year-on-year change?
Over the past year, OPRX annual cash flow from financing activities has changed by +$47.17 M (+248.91%)
What is OptimizeRx quarterly cash flow from financing activities?
The current quarterly CFF of OPRX is -$532.00 K
What is the all time high quarterly CFF for OptimizeRx?
OptimizeRx all-time high quarterly cash flow from financing activities is $70.18 M
What is OptimizeRx quarterly CFF year-on-year change?
Over the past year, OPRX quarterly cash flow from financing activities has changed by -$184.00 K (-52.87%)
What is OptimizeRx TTM cash flow from financing activities?
The current TTM CFF of OPRX is $34.10 M
What is the all time high TTM CFF for OptimizeRx?
OptimizeRx all-time high TTM cash flow from financing activities is $74.02 M
What is OptimizeRx TTM CFF year-on-year change?
Over the past year, OPRX TTM cash flow from financing activities has changed by +$49.51 M (+321.32%)